Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Conditions
Interventions
Insulin Efsitora Alfa
Insulin Degludec
Locations
83
United States
John Muir Physician Network Research Center
Concord, California, United States
Valley Research
Fresno, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Sansum Diabetes Research Institute
Santa Barbara, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Start Date
August 12, 2022
Primary Completion Date
May 7, 2024
Completion Date
May 7, 2024
Last Updated
June 24, 2025
NCT05398783
NCT07224321
NCT01399385
NCT07395050
NCT07340320
NCT07232537
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions